Patents Examined by Blondel Hazel
  • Patent number: 4997645
    Abstract: Disclosed is a method of treating tumors capable of being treated with interferon which is comprised of interferon and dipyridamole, or pharmaceutically acceptable salts thereof, in amounts sufficient to enhance the anti-tumor effect of interferon. Further disclosed is a pharmaceutical composition comprised of interferon and dipyridamole.
    Type: Grant
    Filed: June 16, 1988
    Date of Patent: March 5, 1991
    Assignee: Boehringer Ingelheim GmbH
    Inventors: Nobuo Suzuki, Yoshiaki Takakubo
  • Patent number: 4961969
    Abstract: An approved procedure for the purification and renaturation of biologically active, bacterially produced IFN-.beta. is described. The partially purified material obtained by solubilization of isolated refractile bodies from the recombinant cells is treated to obtain reduction of the protein in the presence of a chaotropic environment and then oxidized after removal of the reducing agent. However, the chaotropic environment is retained during the oxidation. Upon removal of the chaotropic environment, a solubilizing additive is supplied to maintain the IFN-.beta. in solution. Further purification by conventional means may also be effected.
    Type: Grant
    Filed: May 11, 1987
    Date of Patent: October 9, 1990
    Assignee: Cetus Corporation
    Inventors: Susan Hershenson, Ze'ev Shaked, Jody Thomson
  • Patent number: 4962035
    Abstract: A cDNA sequence encoding the .alpha.-subunit of human mast cell IgE surface receptor or an IgE binding fragment thereof.
    Type: Grant
    Filed: December 1, 1987
    Date of Patent: October 9, 1990
    Assignee: President and Fellows of Harvard College
    Inventors: Philip Leder, Akira Shimizu, Reuben Siraganian, Philip Benfey
  • Patent number: 4959210
    Abstract: Condylomata Acuminata infections (anogenital warts) are treated in infected patients by administering liquid nitrogen and immediately thereafter beginning administering recombinant DNA human alpha interferon thrice a week for three weeks.The interferon exemplified is recombinant DNA human interferon alfa-2b in which 1.0.times.10.sup.6 International Units are administered by injection to each lesion.The liquid nitrogen is the cryosurgical agent exemplified and it is topically administered to each lesion by conventional means.
    Type: Grant
    Filed: November 1, 1988
    Date of Patent: September 25, 1990
    Assignee: Schering Corporation
    Inventors: Kenneth A. Smiles, Edwin A. Peets, Daniel J. Tanner
  • Patent number: 4957733
    Abstract: Pharmaceutical product comprising an interferon and a compound of formula (A) ##STR1## or a pro-drug, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative or either of the foregoing as a combined preparation for simultaneous, separate or sequential use in antiviral therapy.
    Type: Grant
    Filed: November 30, 1987
    Date of Patent: September 18, 1990
    Assignee: Beecham Group P.L.C.
    Inventors: Martin Cole, Malcolm R. Boyd, David Sutton
  • Patent number: 4957734
    Abstract: A composition consisting essentially of human leukocyte interferon and an antiviral surfactant, such as the non-ionic surfactant, nonylphenoxypolyethoxy ethanol, and a physiologically acceptable carrier therefor, has been found to be useful for the treatment of malignant and pre-malignant skin lesions and skin lesions associated with herpes zoster and psoriasis by topically administering or applying the composition to the affected skin area.
    Type: Grant
    Filed: July 6, 1987
    Date of Patent: September 18, 1990
    Assignee: Exovir, Inc.
    Inventor: Daniel G. Miller
  • Patent number: 4957906
    Abstract: Disclosed is a pharmaceutical composition containing an aminobenzoic acid derivative as an active ingredient represented by the following general formula: ##STR1## wherein .sup.1 R donotes one member selected from the group consisting of the residual groups formed by removing OH at 1(alpha) or 1(beta) position from arabinose, glucose, galactose and mannose, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 26, 1988
    Date of Patent: September 18, 1990
    Assignee: Kureha Kagaku Kogyo Kabushiki Kaisha
    Inventors: Chikao Yoshikumi, Yoshio Ohmura, Fumio Hirose, Masanori Ikuzawa, Kenichi Matsunaga, Takayoshi Fujii, Minoru Ohhara, Takao Ando
  • Patent number: 4956349
    Abstract: The invention relates to a substantially pure antiinflammatory factor isolated from milk collected from a milk producing animal, to the purification, identification, and characterization of said factor, and to a method for treating inflammation in an animal which comprises administering to the animal an anti-inflammatorally effective amount of the anti-inflammatory factor. In a preferred embodiment, the factor is isolated from milk is produced by a milk producing animal maintained in a hyperimmunized state.
    Type: Grant
    Filed: April 4, 1988
    Date of Patent: September 11, 1990
    Assignee: Stolle Research & Development Corporation
    Inventor: Lee R. Beck
  • Patent number: 4954449
    Abstract: A human monoclonal antibody produced by a self-reproducing carrier cell, antibody being reactive with PRP capsular polysaccharide. Also disclosed is a process of preparing the antibody from the carrier cell, which is conveniently a hybridoma. Additionally, diagnostic, prophylactic and therapeutic compositions and methods employing the antibody are disclosed. Moreover, a laboratory reagent containing the antibody is described.
    Type: Grant
    Filed: February 12, 1988
    Date of Patent: September 4, 1990
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Kenneth W. Hunter, Gerald W. Fischer
  • Patent number: 4950470
    Abstract: The present disclosure is directed to improved pharmaceutical compositions employing interferon-gamma which have been treated to remove interferon-gamma inhibitory activity associated with such preparations. In addition, the present disclosure details treatment protocols, including the elevation of patient body temperature and the use of combined or sequential interferon-gamma treatments, to enhance interferon-gamma efficacy and reduce the resistance associated with interferon-alpha and/or beta therapy.
    Type: Grant
    Filed: October 6, 1986
    Date of Patent: August 21, 1990
    Assignee: Board of Regents, The University of Texas System
    Inventor: W. Robert Fleischmann
  • Patent number: 4948730
    Abstract: Compositions and methods for their use in modulating animal cellular responses are disclosed. The compositions include as an active agent an effective amount of an 8-substituted guanine derivative bonded 9-1' to an aldose having 5 or 6 carbon atoms in the aldose chain. The composition includes a diluent amount of a physiologically tolerable carrier. The guanine derivative is free of electrically charged funtionality, while the 8-substituent has an electron withdrawing inductive effector greater than that of hydrogen and contains fewer than about 15 atoms. Anmimal cellular responses are modulated by contacting the cells with a composition of this invention.
    Type: Grant
    Filed: June 6, 1989
    Date of Patent: August 14, 1990
    Assignee: Scripps Clinic and Research Foundation
    Inventors: Michael G. Goodman, William O. Weigle
  • Patent number: 4946674
    Abstract: This invention relates to the treatment of rheumatic diseases. More particularly, this invention relates to processes and compositions for treating rheumatic diseases by administering to a patient a pharmaceutically effect amount of gamma interferon.
    Type: Grant
    Filed: September 30, 1985
    Date of Patent: August 7, 1990
    Assignee: Bioferon Biochemische Substanzen GmbH & Co.
    Inventors: Johann-Friedrich von Eichborn, Hans-Joachim Obert, Franz Link
  • Patent number: 4944941
    Abstract: Disclosed are improved methods for the treatment of lung membrane diseases such as respiratory distress syndrome (RDS) or idiopathic RDS, employing compositions including therapeutically effective amounts of gamma interferon and/or tumor necrosis factor (TNF), each alone or in combination with corticosteroids, preferably employing recombinant human gamma interferon and/or TNF. Individuals, including adults or children, are administered amounts of these agents that are generally effective to induce the lungs of affected individuals to produce one or more surfactant components, including both phospholipid and surfactant protein substituents.
    Type: Grant
    Filed: August 7, 1987
    Date of Patent: July 31, 1990
    Assignee: Genentech, Inc.
    Inventor: Arthur J. Ammann
  • Patent number: 4939088
    Abstract: A recombinant DNA expression vector comprising an Epstein-Barr virus origin of replication, an EBNA-1 gene, a selectable marker expression cassette and a human gamma interferon expression cassette comprising a promoter region, an open reading frame encoding human gamma interferon and a polyadenylation region; a mammalian host cell transformed by said vector; and a process for producing human gamma interferon using said transformed mammalian host cell.
    Type: Grant
    Filed: February 18, 1987
    Date of Patent: July 3, 1990
    Assignee: Meloy Laboratories Inc.
    Inventors: Janet M. Young, Nava Sarver, William N. Drohan
  • Patent number: 4935233
    Abstract: Described is a new class of polypeptide cell modulators characterized by being composed of two covalently linked cell modulators in a linear polypeptide sequence. Such dual function polypeptides have new and particularly useful activities when the component polypeptide cell modulators are interferons, lymphokines or cytotoxins which act through different and specific cell receptors to initiate complementary biological activities.
    Type: Grant
    Filed: December 2, 1985
    Date of Patent: June 19, 1990
    Assignee: G. D. Searle and Company
    Inventors: Leslie D. Bell, Keith G. McCullagh, Alan G. Porter
  • Patent number: 4929442
    Abstract: Compositions containing a tissue plasminogen activator (t-PA), epidermal growth factor (EGF), transforming growth factor-alpha (TGF.alpha.), transforming growth factor-beta (TGF-.beta.), human endothelial cell growth factor (ECGF), granulocyte macrophage colony stimulating factor (GM-CSF) and a fibronectin or large external transformation sensitive protein (LETS) including cell surface protein (CSP), cell adhesion protein (CAP), cell insoluble globulin (CIG) and/or opsonic-alpha 2 surface binding glycoprotein in a suitable physiologically acceptable carrier are useful for the treatment of humans when topically and/or subcutaneously applied. These compositions might also usefully contain or have employed in association therewith an adjuvant to aid in the transdermal transport or transfer of the compositions, particularly the active components therein, through or across the skin.
    Type: Grant
    Filed: September 26, 1986
    Date of Patent: May 29, 1990
    Assignee: Exovir, Inc.
    Inventor: Maxwell M. Powell
  • Patent number: 4929443
    Abstract: Methods and means for treating interferon-sensitive diseases are disclosed, wherein a whole blood sample is taken from a patient suffering from such disease and is incubated in vitro together with a mitogen to produce .gamma.-interferon. After incubation the whole blood sample is subjected to a separation step for producing a blood plasma product, which is free from the mitogen but contains .gamma.-interferon. This blood plasma product is used for re-administration to the patient from which the whole blood sample was taken.
    Type: Grant
    Filed: May 18, 1987
    Date of Patent: May 29, 1990
    Inventors: Ragnvald E. Lindblom, Ulf S. Rothman
  • Patent number: 4925831
    Abstract: Disclosed are specific aminoalkyl naphthalenediol derivatives that enhance natural human host resistance to viral infectious organisms and particularly AIDS-related viruses. Such agents are also administered prophylactically to individuals whose resistance to infection has been specifically immunocompromised by an AIDs-related (HIV) virus.
    Type: Grant
    Filed: June 11, 1987
    Date of Patent: May 15, 1990
    Assignee: Merck & Co., Inc.
    Inventor: Philippe L. Durette
  • Patent number: 4923852
    Abstract: Disclosed are specific aminoalkyl naphthalenediol derivatives that enhance natural human host resistance to viral infectious organisms and particularly AIDS-related viruses. Such agents are also administered prophylactically to individuals whose resistance to infection has been specifically immunocompromised by an AIDS-related (HIV) virus.
    Type: Grant
    Filed: June 11, 1987
    Date of Patent: May 8, 1990
    Assignee: Merck & Co., Inc.
    Inventor: Philippe L. Durette
  • Patent number: RE33403
    Abstract: A method for treating vascular disorders or pulmonary disorders associated with smoking in an animal which comprises: adminstering to the animal milk collected from a bovid being maintained in a hyperimmune state, in an amount and for a time sufficient to produce anti arteriosclerotic or antiaging vascular effects or sparing effects on lung tissue.
    Type: Grant
    Filed: January 13, 1989
    Date of Patent: October 23, 1990
    Assignee: Stolle Research & Development Corporation
    Inventors: Ralph J. Stolle, Lee R. Beck